Dianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $158.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 119.17% from the stock’s previous close.

Several other brokerages also recently commented on DNTH. Truist Financial raised their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Citigroup initiated coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Finally, Wedbush raised their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $129.83.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH traded down $2.44 during trading hours on Thursday, hitting $72.09. The company had a trading volume of 1,053,338 shares, compared to its average volume of 930,985. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -17.37 and a beta of 1.35. Dianthus Therapeutics has a 52 week low of $32.22 and a 52 week high of $117.88. The firm has a 50 day simple moving average of $100.04 and a 200 day simple moving average of $94.44.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, research analysts forecast that Dianthus Therapeutics will post -3.81 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 23,124 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. The trade was a 85.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Edward Carr sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the completion of the transaction, the chief accounting officer directly owned 20,000 shares in the company, valued at approximately $2,027,600. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 242,429 shares of company stock valued at $26,118,913. 3.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently modified their holdings of the company. Eagle Bay Advisors LLC bought a new position in Dianthus Therapeutics during the 3rd quarter valued at approximately $218,000. Assenagon Asset Management S.A. raised its holdings in Dianthus Therapeutics by 160.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock worth $64,474,000 after purchasing an additional 451,597 shares in the last quarter. Sax Wealth Advisors LLC purchased a new stake in shares of Dianthus Therapeutics in the 3rd quarter worth about $203,000. GAMMA Investing LLC boosted its stake in shares of Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after purchasing an additional 254 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of Dianthus Therapeutics by 5.7% during the 2nd quarter. Arizona State Retirement System now owns 10,141 shares of the company’s stock valued at $989,000 after purchasing an additional 546 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.